Skip to Content

872 Results Found

  • Review
  • Open Access
1 Citations
1,715 Views
12 Pages

MDM4 at the Crossroads: Beyond p53 and MDM2

  • Dipesh Thapa,
  • Allison St. John,
  • Alejandro Parrales,
  • Atul Ranjan and
  • Tomoo Iwakuma

25 March 2026

MDM4 (Murine Double Minute 4), also known as MDMX, is a crucial negative regulator of the tumor suppressor p53. MDM4 heterodimerizes with MDM2 to enhance MDM2-mediated ubiquitination and degradation of p53, thereby promoting tumorigenesis. Beyond its...

(This article belongs to the Special Issue Oncoproteins in Cancers: Transcriptional Regulation, Signaling and Targeted Therapy)
  • Article
  • Open Access
17 Citations
5,927 Views
16 Pages

15 February 2020

Dysfunction of the tumor suppressor p53 occurs in most human cancers. Mdm2 and MdmX are homologous proteins from the Mdm (Murine Double Minute) protein family, which play a critical role in p53 inactivation and degradation. The two proteins interact...

(This article belongs to the Special Issue Biocatalysis: Mechanisms of Proteolytic Enzymes)
  • Article
  • Open Access
13 Citations
4,308 Views
25 Pages

Comparison of miRNA Expression Profiles between HIV-1 and HIV-2 Infected Monocyte-Derived Macrophages (MDMs) and Peripheral Blood Mononuclear Cells (PBMCs)

  • Santanu Biswas,
  • Emily Chen,
  • Mohan Haleyurgirisetty,
  • Sherwin Lee and ,
  • Indira Hewlett and
  • Krishnakumar Devadas
  • + 1 author+ 0 author

22 September 2020

During the progression of HIV-1 infection, macrophage tropic HIV-1 that use the CCR5 co-receptor undergoes a change in co-receptor use to CXCR4 that is predominately T cell tropic. This change in co-receptor preference makes the virus able to infect...

(This article belongs to the Special Issue Functional Genomics in Health and Disease)
  • Review
  • Open Access
23 Citations
8,484 Views
18 Pages

Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction

  • Ye Huang,
  • Wang Li,
  • Yuke Zhou,
  • Jinping Bai and ,
  • Ning Li,
  • Zhengding Su and
  • Xiyao Cheng
  • + 2 authors+ 0 author

12 April 2025

p53 is a tumor suppressor gene and is regarded as one of the most crucial genes in protecting humans against cancer. The protein Mdm2 and its homolog MdmX serve as negative regulators of p53. In nearly half of cancer cells, there is an overexpression...

(This article belongs to the Section Cell Signaling)
  • Review
  • Open Access
4 Citations
2,706 Views
15 Pages

Mechanistic Role of the Mdm2/MdmX Lid Domain in Regulating Their Interactions with p53

  • Qiuyin Wei,
  • Chenqi Li,
  • Yibing Tang,
  • Jinping Bai and ,
  • Wang Li,
  • Jidong Liu,
  • Zhengding Su and
  • Xiyao Cheng
  • + 3 authors+ 0 author

30 April 2025

p53 functions as a critical guardian of the genome, orchestrating tumor suppression pathways and ensuring the integrity of chromosomal stability. Mdm2 and MdmX, homologous proteins, serve as negative feedback regulators of p53. In approximately half...

(This article belongs to the Section Biomacromolecules: Proteins, Nucleic Acids and Carbohydrates)
  • Article
  • Open Access
34 Citations
12,854 Views
14 Pages

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells

  • Zuzana Mrkvová,
  • Stjepan Uldrijan,
  • Antonio Pombinho,
  • Petr Bartůněk and
  • Iva Slaninová

Tumor suppressor p53 is mutated in about 50% of cancers. Most malignant melanomas carry wild-type p53, but p53 activity is often inhibited due to overexpression of its negative regulators Mdm2 or MdmX. We performed high throughput screening of 2448 c...

(This article belongs to the Special Issue Bioactive Molecules and Their Mechanisms of Action)
  • Article
  • Open Access
15 Citations
4,593 Views
11 Pages

Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer

  • Agnė Bartnykaitė,
  • Aistė Savukaitytė,
  • Rasa Ugenskienė,
  • Monika Daukšaitė and ,
  • Erika Korobeinikova,
  • Jurgita Gudaitienė and
  • Elona Juozaitytė
  • + 2 authors+ 0 author

19 February 2021

Breast cancer is one of the most common cancers worldwide. Single nucleotide polymorphisms (SNPs) in MDM2 and MDM4 have been associated with various cancers. However, the influence on clinical characteristics of breast cancer has not been sufficientl...

(This article belongs to the Special Issue New Therapeutic Approaches, Biomarkers for Diagnosis, Prognosis and Therapy Prediction in Breast Cancer and Breast Cancer Recurrence)
  • Review
  • Open Access
23 Citations
5,793 Views
6 Pages

Targeting MDM4 Splicing in Cancers

  • Boris Bardot and
  • Franck Toledo

20 February 2017

MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild‐type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms:...

(This article belongs to the Special Issue Therapeutic Alternative Splicing: Mechanisms and Applications)
  • Article
  • Open Access
5 Citations
4,623 Views
14 Pages

Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells

  • Rati Lama,
  • Joseph M. Fose,
  • Diana Martín,
  • Inés G. Muñoz and ,
  • Eunice S. Wang,
  • Pamela J. Sung,
  • Sherry R. Chemler and
  • Xinjiang Wang
  • + 3 authors+ 0 author

5 January 2025

MDM2 and MDM4 are major negative regulators of tumor suppressor p53. Beyond regulating p53, MDM2 possesses p53-independent activity in promoting cell cycle progression and tumorigenesis via its RING domain ubiquitin E3 ligase activity. MDM2 and MDM4...

(This article belongs to the Special Issue Small-Molecule Inhibitors: Synthesis, Cytotoxicity and Biological Activities)
  • Article
  • Open Access
1 Citations
3,103 Views
20 Pages

Analysis of p53-Independent Functions of the Mdm2-MdmX Complex Using Data-Independent Acquisition-Based Profiling

  • Anu Jain,
  • Rafaela Muniz de Queiroz,
  • Jayanta K. Chakrabarty,
  • Karl A. T. Makepeace and ,
  • Carol Prives and
  • Lewis M. Brown
  • + 1 author+ 0 author

Background: We utilized data-independent acquisition (DIA) to study the poorly understood biology of Mdm2 and MdmX in a p53-null context. Mdm2 and MdmX form an E3-ligase complex that has as its most well-studied function the negative regulation of th...

  • Article
  • Open Access
4 Citations
2,956 Views
14 Pages

Sex-Specific Associations of MDM2 and MDM4 Variants with Risk of Multiple Primary Melanomas and Melanoma Survival in Non-Hispanic Whites

  • Sarah V. Ward,
  • Isidora Autuori,
  • Li Luo,
  • Emily LaPilla and ,
  • Sarah Yoo,
  • Ajay Sharma,
  • Klaus J. Busam,
  • David W. Olilla,
  • Terence Dwyer and
  • Irene Orlow
  • + 15 authors+ 10 authors

11 May 2023

MDM2-SNP309 (rs2279744), a common genetic modifier of cancer incidence in Li-Fraumeni syndrome, modifies risk, age of onset, or prognosis in a variety of cancers. Melanoma incidence and outcomes vary by sex, and although SNP309 exerts an effect on th...

(This article belongs to the Section Cancer Epidemiology and Prevention)
  • Article
  • Open Access
6 Citations
2,546 Views
14 Pages

Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression

  • Konstantinos I. Tosios,
  • Eleni-Marina Kalogirou and
  • Ioannis G. Koutlas

13 February 2024

Ameloblastoma is a rare tumor but represents the most common odontogenic neoplasm. It is localized in the jaws and, although it is a benign, slow-growing tumor, it has an aggressive local behavior and high recurrence rate. Therefore, alternative trea...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
67 Citations
7,527 Views
16 Pages

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

  • Andrea Forschner,
  • Franz-Joachim Hilke,
  • Irina Bonzheim,
  • Axel Gschwind and ,
  • German Demidov,
  • Teresa Amaral,
  • Stephan Ossowski,
  • Olaf Riess,
  • Christopher Schroeder and
  • Tobias Sinnberg
  • + 10 authors+ 5 authors

26 February 2020

Background: Mucosal and acral melanoma respond worse to immune checkpoint inhibitors (ICI) than cutaneous melanoma. MDM2/4 as well as EGFR amplifications are supposed to be associated with hyperprogression on ICI in diverse cancers. We therefore inve...

  • Article
  • Open Access
5 Citations
3,615 Views
17 Pages

13 April 2021

Murine double minute 2 (MDM2), a negative regulator of the p53 tumor suppressor protein, is overexpressed in several human cancers. Herein we investigate the feasibility of developing 18F-labeled compounds based on the small molecule inhibitor SP-141...

(This article belongs to the Special Issue Targets, Tracers and Translation, Part 2 - New Horizons in Radiopharmaceutical Development)
  • Article
  • Open Access
13 Citations
3,865 Views
16 Pages

Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study

  • Florin Tripon,
  • Mihaela Iancu,
  • Adrian Trifa,
  • George Andrei Crauciuc and ,
  • Alina Boglis,
  • Beata Balla,
  • Adriana Cosma,
  • Delia Dima,
  • Marcela Candea and
  • Claudia Banescu
  • + 7 authors+ 2 authors

This study aimed to explore the associations between the TP53 rs1042522 (TP53 Arg72Pro), MDM2 rs2279744 (MDM2 309T>G), rs3730485 (MDM2 del1518), MDM4 rs4245739 (MDM4 34091 C>A) variants and odds of developing acute myeloid leukemia (AML) in a c...

(This article belongs to the Special Issue Advances in Acute Myeloid Leukemia)
  • Article
  • Open Access
16 Citations
3,850 Views
13 Pages

Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain

  • Viktoria K. Ilic,
  • Olga Egorova,
  • Ernest Tsang,
  • Milena Gatto and ,
  • Yi Wen,
  • Yong Zhao and
  • Yi Sheng
  • + 2 authors+ 0 author

27 April 2022

The proto-oncogene MDM2 is frequently amplified in many human cancers and its overexpression is clinically associated with a poor prognosis. The oncogenic activity of MDM2 is demonstrated by its negative regulation of tumor suppressor p53 and the sub...

(This article belongs to the Special Issue The Ubiquitin Proteasome System (UPS) in Pathogenesis and Diseases)
  • Article
  • Open Access
2 Citations
1,993 Views
16 Pages

Oncogenic Functions of Alternatively Spliced MDM2-ALT2 Isoform in Retroperitoneal Liposarcoma

  • Fernanda Costas C. de Faria,
  • Safiya Khurshid,
  • Patricia Sarchet,
  • Sayumi Tahara and ,
  • Lucia Casadei,
  • Valerie Grignol,
  • Roma Karna,
  • Sydney Rentsch,
  • Nipin Sp and
  • Raphael E. Pollock
  • + 13 authors+ 8 authors

17 December 2024

Retroperitoneal liposarcoma (RPLPS) is one of the most common histologic subtypes of soft tissue sarcoma (STS). Complete surgical resection remains the mainstay treatment, while the high rate of locoregional recurrence constitutes the predominant cau...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
5 Citations
3,251 Views
15 Pages

7 February 2026

The p53 tumor suppressor protein plays a central role in maintaining genomic stability by regulating cell cycle arrest, apoptosis, and DNA repair under cellular stress. Mouse double minute 2 (MDM2), an E3 ubiquitin ligase, negatively regulates p53 vi...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
11 Citations
4,419 Views
16 Pages

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

  • Francesco Russano,
  • Mattia Sturlese,
  • Luigi Dall’Olmo,
  • Francesco Callegarin and ,
  • Davide Brugnolo,
  • Paolo Del Fiore,
  • Vittoria Patti,
  • Arianna Purpura,
  • Stefano Moro and
  • Simone Mocellin
  • + 6 authors+ 1 author

The Murine Double Minute 2 (MDM2) gene encodes an E3 ubiquitin ligase that negatively regulates the tumor suppressor p53, maintaining low p53 levels through ubiquitination and proteasomal degradation. MDM2 overexpression in various malignancies leads...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
10 Citations
5,254 Views
17 Pages

Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC

  • Rossella Pellegrino,
  • Abhishek Thavamani,
  • Diego F. Calvisi,
  • Jan Budczies and ,
  • Ariane Neumann,
  • Robert Geffers,
  • Jasmin Kroemer,
  • Damaris Greule,
  • Peter Schirmacher and
  • Thomas Longerich
  • + 6 authors+ 1 author

8 January 2021

Different molecular mechanisms support the overexpression of the mouse double minute homolog 4 (MDM4), a functional p53 inhibitor, in human hepatocellular carcinoma (HCC). However, the transcription factors (TFs) leading to its transcriptional upregu...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
7 Citations
3,729 Views
11 Pages

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells

  • Yuta Mitobe,
  • Shuhei Suzuki,
  • Yurika Nakagawa-Saito,
  • Keita Togashi and ,
  • Asuka Sugai,
  • Yukihiko Sonoda,
  • Chifumi Kitanaka and
  • Masashi Okada
  • + 3 authors+ 0 author

30 August 2023

The development of MDM4 inhibitors as an approach to reactivating p53 in human cancer is attracting increasing attention; however, whether they affect the function of MDM2 and how they interact with MDM2 inhibitors remain unknown. We addressed this q...

(This article belongs to the Special Issue The 10th International MDM2 Workshop—Opening Up New Avenues for MDM2 and p53 Research)
  • Article
  • Open Access
6 Citations
2,871 Views
13 Pages

Ribosomal Protein S4 X-Linked as a Novel Modulator of MDM2 Stability by Suppressing MDM2 Auto-Ubiquitination and SCF Complex-Mediated Ubiquitination

  • Satsuki Ryu,
  • Hiroki Nakashima,
  • Yuka Tanaka,
  • Risa Mukai and ,
  • Yasuhiro Ishihara,
  • Takashi Tominaga and
  • Takayuki Ohshima
  • + 2 authors+ 0 author

23 July 2024

Mouse double minute 2 (MDM2) is an oncoprotein that is frequently overexpressed in tumors and enhances cellular transformation. Owing to the important role of MDM2 in modulating p53 function, it is crucial to understand the mechanism underlying the r...

(This article belongs to the Section Molecular Biology)
  • Article
  • Open Access
31 Citations
13,736 Views
15 Pages

FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations

  • Alessandro Gambella,
  • Luca Bertero,
  • Milena Rondón-Lagos,
  • Ludovica Verdun Di Cantogno and ,
  • Nelson Rangel,
  • Chiara Pitino,
  • Alessia Andrea Ricci,
  • Luca Mangherini,
  • Isabella Castellano and
  • Paola Cassoni
  • + 5 authors+ 0 author

10 January 2023

MDM2 amplification represents the leading oncogenic pathway and diagnostic hallmark of liposarcoma, whose assessment is based on Fluorescence In Situ Hybridization (FISH) analysis. Despite its diagnostic relevance, no univocal interpretation criteria...

(This article belongs to the Collection Feature Papers in Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
18 Citations
5,838 Views
24 Pages

Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role of MDM2 Amplification/Co-Amplification and MDM2 Immunostaining

  • Claudiu Nistor,
  • Camelia Stanciu Gavan,
  • Adelina Birceanu,
  • Cezar Betianu and ,
  • Mara Carsote,
  • Anca-Pati Cucu,
  • Mihaela Stanciu,
  • Florina Ligia Popa,
  • Adrian Ciuche and
  • Mihai-Lucian Ciobica
  • + 5 authors+ 0 author

Primary cardiac tumours are relatively uncommon (75% are benign). Across the other 25%, representing malignant neoplasia, sarcomas account for 75–95%, and primary cardiac intimal sarcoma (PCIS) is one of the rarest findings. We aimed to present a com...

(This article belongs to the Special Issue New Advances in Thoracic Surgery: Clinical Diagnosis, Treatment, and Prognosis)
  • Review
  • Open Access
26 Citations
11,525 Views
18 Pages

Controlling the Mdm2-Mdmx-p53 Circuit

  • David L. Waning,
  • Jason A. Lehman,
  • Christopher N. Batuello and
  • Lindsey D. Mayo

18 May 2010

The p53 tumor suppressor is a key protein in maintaining the integrity of the genome by inducing either cell cycle arrest or apoptosis following cellular stress signals. Two human family members, Mdm2 and Mdmx, are primarily responsible for inactivat...

(This article belongs to the Special Issue Protein Kinase Inhibitors)
  • Commentary
  • Open Access
5 Citations
2,356 Views
11 Pages

The Role of Nuclear Phosphoinositides in the p53-MDM2 Nexus

  • Jeong Hyo Lee,
  • Muhammad Khalil Salah,
  • Xiangqin Chen,
  • Nickolas Vladimir Kucherenko and ,
  • Vincent L. Cryns and
  • Richard A. Anderson
  • + 1 author+ 0 author

22 July 2025

Recent insights into the p53-MDM2 nexus have advanced deeper understanding of their regulation and potent impact on cancer heterogeneity. The roles of nuclear phosphoinositide (PIPns) in modulating this pathway are emerging as a key mechanism. Here,...

(This article belongs to the Section Cell Microenvironment)
  • Review
  • Open Access
33 Citations
13,169 Views
20 Pages

The Role of MDM2 in Promoting Genome Stability versus Instability

  • M. Reza Saadatzadeh,
  • Adily N. Elmi,
  • Pankita H. Pandya,
  • Khadijeh Bijangi-Vishehsaraei and ,
  • Jixin Ding,
  • Christopher W. Stamatkin,
  • Aaron A. Cohen-Gadol and
  • Karen E. Pollok
  • + 3 authors+ 0 author

23 October 2017

In cancer, the mouse double minute 2 (MDM2) is an oncoprotein that contributes to the promotion of cell growth, survival, invasion, and therapeutic resistance. The impact of MDM2 on cell survival versus cell death is complex and dependent on levels o...

(This article belongs to the Special Issue Mechanisms Leading to Genomic Instability)
  • Article
  • Open Access
23 Citations
4,840 Views
13 Pages

Chemopreventive Agent 3,3′-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells

  • Xiang Gao,
  • Jingwen Liu,
  • Kwang Bog Cho,
  • Samanthreddy Kedika and
  • Bin Guo

3,3′-Diindolylmethane (DIM) is a naturally derived chemopreventive compound. It comes from glucobrassicin, an indole glucosinolate enriched in cruciferous vegetables, and is formed in the acidic environment of the stomach after ingestion. Mouse...

(This article belongs to the Special Issue The Effect of Dietary Factors on Cancer 2.0)
  • Article
  • Open Access
5 Citations
3,148 Views
22 Pages

13 November 2020

Most low-penetrance genetic risk factors for cancer are located in noncoding regions, presumably altering the regulation of neighboring genes. The poorly characterized Indel polymorphism rs150550023 (rs3730485; del1518) in the promoter of MDM2 (human...

(This article belongs to the Special Issue Molecular Genetics of Breast and Ovary Cancer)
  • Article
  • Open Access
27 Citations
6,155 Views
20 Pages

MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters

  • Kester Mo Henningsen,
  • Valentina Manzini,
  • Anna Magerhans,
  • Sabrina Gerber and
  • Matthias Dobbelstein

24 December 2021

MDM2 is the principal antagonist of the tumor suppressor p53. p53 binds to its cognate DNA element within promoters and activates the transcription of adjacent genes. These target genes include MDM2. Upon induction by p53, the MDM2 protein binds and...

(This article belongs to the Collection p53 Function and Dysfunction in Human Health and Diseases)
  • Article
  • Open Access
6 Citations
3,616 Views
20 Pages

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4

  • Rossella Lucà,
  • Giorgia di Blasio,
  • Daniela Gallo,
  • Valentina Monteleone and ,
  • Isabella Manni,
  • Laura Fici,
  • Marianna Buttarelli,
  • Germana Ciolli,
  • Marsha Pellegrino and
  • Fabiola Moretti
  • + 14 authors+ 9 authors

12 September 2019

Estrogen activity towards cancer-related pathways can impact therapeutic intervention. Recent omics data suggest possible crosstalk between estrogens/gender and MDM4, a key regulator of p53. Since MDM4 can either promote cell transformation or enhanc...

  • Review
  • Open Access
34 Citations
14,841 Views
19 Pages

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

  • Karolina I. Pellot Ortiz,
  • Julian S. Rechberger,
  • Leo F. Nonnenbroich,
  • David J. Daniels and
  • Jann N. Sarkaria

Inhibition of the interaction between MDM2 and p53 has emerged as a promising strategy for combating cancer, including the treatment of glioblastoma (GBM). Numerous MDM2 inhibitors have been developed and are currently undergoing rigorous testing for...

(This article belongs to the Special Issue Gliomas: Signaling Pathways, Molecular Mechanisms and Therapeutic Approaches)
  • Article
  • Open Access
10 Citations
5,755 Views
9 Pages

NORE1A Regulates MDM2 Via β-TrCP

  • M. Lee Schmidt,
  • Diego F. Calvisi and
  • Geoffrey J. Clark

23 March 2016

Mouse Double Minute 2 Homolog (MDM2) is a key negative regulator of the master tumor suppressor p53. MDM2 regulates p53 on multiple levels, including acting as an ubiquitin ligase for the protein, thereby promoting its degradation by the proteasome....

(This article belongs to the Special Issue RASSF Signalling in Cancer)
  • Review
  • Open Access
93 Citations
15,690 Views
15 Pages

Murine Double Minute Clone 2, located at 12q15, is an oncogene that codes for an oncoprotein of which the association with p53 was discovered 30 years ago. The most important function of MDM2 is to control p53 activity; it is in fact the best documen...

(This article belongs to the Special Issue Molecular Classification of Soft Tissue and Bone Tumors)
  • Article
  • Open Access
2 Citations
2,597 Views
19 Pages

30 August 2024

MDM4 is upregulated in the majority of melanoma cases and has been described as a “key therapeutic target in cutaneous melanoma”. Numerous isoforms of MDM4 exist, with few studies examining their specific expression in human tissues. The...

(This article belongs to the Special Issue Cancer Genomics)
  • Article
  • Open Access
19 Citations
6,111 Views
31 Pages

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

  • Partha Biswas,
  • Shabana Bibi,
  • Qudsia Yousafi,
  • Asim Mehmood and ,
  • Shahzad Saleem,
  • Awais Ihsan,
  • Dipta Dey,
  • Md. Nazmul Hasan Zilani,
  • Md. Nazmul Hasan and
  • Mohamed M. Abdel-Daim
  • + 8 authors+ 3 authors

27 March 2023

An evaluation of the expression and predictive significance of the MDM2 gene in brain lower-grade glioma (LGG) cancer was carried out using onco-informatics pipelines. Several transcriptome servers were used to measure the differential expression of...

(This article belongs to the Special Issue Advances in Computational Chemistry for Drug Design, Discovery and Screening)
  • Review
  • Open Access
14 Citations
6,696 Views
14 Pages

24 May 2023

Murine double minute 2 (MDM2, gene name MDM2) is an oncogene that mainly codes for a protein that acts as an E3 ubiquitin ligase, which targets the tumor suppressor protein p53 for degradation. Overexpression of MDM2 regulates the p53 protein levels...

(This article belongs to the Section Oncology)
  • Feature Paper
  • Review
  • Open Access
14 Citations
6,976 Views
15 Pages

Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy

  • Wei Wang,
  • Atif Zafar,
  • Mehrdad Rajaei and
  • Ruiwen Zhang

9 May 2020

The tumor suppressor p53 is believed to be the mostly studied molecule in modern biomedical research. Although p53 interacts with hundreds of molecules to exert its biological functions, there are only a few modulators regulating its expression and f...

(This article belongs to the Section Cellular Pathology)
  • Article
  • Open Access
17 Citations
6,068 Views
14 Pages

MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models

  • Andrew Patt,
  • Bryce Demoret,
  • Colin Stets,
  • Kate-Lynn Bill and ,
  • Philip Smith,
  • Anitha Vijay,
  • Andrew Patterson,
  • John Hays,
  • Mindy Hoang and
  • Ewy A. Mathé
  • + 6 authors+ 1 author

4 August 2020

Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS patients with higher MDM2 amplification have lower chemotherapy sensitivity and worse outcome t...

(This article belongs to the Special Issue Management of Soft Tissue Sarcomas and GIST)
  • Article
  • Open Access
28 Citations
5,689 Views
23 Pages

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma

  • Omar Faruq,
  • Davidson Zhao,
  • Mariusz Shrestha,
  • Andrea Vecchione and ,
  • Eldad Zacksenhaus and
  • Hong Chang
  • + 1 author+ 0 author

21 March 2022

Background: MDM2 is elevated in multiple myeloma (MM). Although traditionally, MDM2 negatively regulates p53, a growing body of research suggests that MDM2 plays several p53-independent roles in cancer pathogenesis as a regulator of oncogene mRNA sta...

  • Article
  • Open Access
3 Citations
2,529 Views
11 Pages

Expression and Clinical Significance of MDM2 in Non-Functioning PitNETs

  • Xiaohui Yao,
  • Qian Liu,
  • Sida Zhao,
  • Rui Cheng and ,
  • Chunhui Liu and
  • Gangli Zhang
  • + 1 author+ 0 author

15 February 2023

Background and Objective: Non-functioning pituitary neuroendocrine tumors (NF-PitNETs) represent a heterogeneous tumor type that lacks effective medical treatment. MDM2, the main negative regulator of p53, binds to and forms a stable complex with p53...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
8 Citations
2,994 Views
17 Pages

MDM2 Influences ACE2 Stability and SARS-CoV-2 Uptake

  • Quirin Emslander,
  • Karsten Krey,
  • Sabri Hamad,
  • Susanne Maidl and ,
  • Lila Oubraham,
  • Joshua Hesse,
  • Alexander Henrici,
  • Katharina Austen,
  • Julia Mergner and
  • Andreas Pichlmair
  • + 6 authors+ 1 author

18 August 2023

Angiotensin-converting enzyme 2 (ACE2) is the central entry receptor for SARS-CoV-2. However, surprisingly little is known about the effects of host regulators on ACE2 localization, expression, and the associated influence on SARS-CoV-2 infection. He...

(This article belongs to the Special Issue The Secret Life of ACE2 as a Receptor for the Coronaviruses)
  • Article
  • Open Access
3 Citations
2,169 Views
21 Pages

Conformational Stability of the N-Terminal Region of MDM2

  • Bruno Rizzuti,
  • Olga Abian,
  • Adrián Velazquez-Campoy and
  • José L. Neira

14 November 2023

MDM2 is an E3 ubiquitin ligase which is crucial for the degradation and inhibition of the key tumor-suppressor protein p53. In this work, we explored the stability and the conformational features of the N-terminal region of MDM2 (N-MDM2), through whi...

(This article belongs to the Special Issue Protein Folding, towards the Comprehensive Understanding from Various Aspects)
  • Article
  • Open Access
7 Citations
4,667 Views
22 Pages

p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors

  • Immacolata Maietta,
  • Francesca Del Peschio,
  • Preziosa Buonocore,
  • Eleonora Viscusi and ,
  • Stefano Laudati,
  • Giuseppe Iannaci,
  • Michele Minopoli,
  • Maria Letizia Motti and
  • Valentina De Falco
  • + 4 authors+ 0 author

25 December 2022

The expression level of the tumor suppressor p53 is controlled by the E3 ubiquitin ligase MDM2 with a regulatory feedback loop, which allows p53 to upregulate its inhibitor MDM2. In this manuscript we demonstrated that p90RSK binds and phosphorylates...

(This article belongs to the Special Issue Targeting Therapies for the p53 Protein in Cancer Treatments)
  • Article
  • Open Access
9 Citations
3,052 Views
14 Pages

Impact of Reactive Oxygen and Nitrogen Species Produced by Plasma on Mdm2–p53 Complex

  • Pankaj Attri,
  • Hirofumi Kurita,
  • Kazunori Koga and
  • Masaharu Shiratani

3 September 2021

The study of protein–protein interactions is of great interest. Several early studies focused on the murine double minute 2 (Mdm2)–tumor suppressor protein p53 interactions. However, the effect of plasma treatment on Mdm2 and p53 is still absent from...

(This article belongs to the Special Issue Plasma Biology)
  • Article
  • Open Access
6 Citations
4,392 Views
21 Pages

Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance

  • Marcin Herok,
  • Bartosz Wawrzynow,
  • Marta J. Maluszek,
  • Maciej B. Olszewski and ,
  • Alicja Zylicz and
  • Maciej Zylicz
  • + 1 author+ 0 author

7 September 2021

Analyzing the TCGA breast cancer database, we discovered that patients with the HER2 cancer subtype and overexpression of MDM2 exhibited decreased post-treatment survival. Inhibition of MDM2 expression in the SKBR3 cell line (HER2 subtype) diminished...

(This article belongs to the Special Issue DNA Damage in Cancer)
  • Review
  • Open Access
159 Citations
17,203 Views
21 Pages

Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as DNA repair, apoptosis, cell cycle arrest, senescence, metabolism, and autophagy. One of the genes that p53 ac...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
12 Citations
12,461 Views
10 Pages

SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw

  • Adepitan A. Owosho,
  • Adeola M. Ladeji,
  • Olufunlola M. Adesina,
  • Kehinde E. Adebiyi and ,
  • Mofoluwaso A. Olajide,
  • Toluwaniyin Okunade,
  • Jacob Palmer,
  • Temitope Kehinde,
  • Jeffrey A. Vos and
  • Kurt F. Summersgill
  • + 6 authors+ 1 author

30 December 2021

Primary osteosarcomas of the jaw (OSJ) are rare, accounting for 6% of all osteosarcomas. This study aims to determine the value of SATB2 and MDM2 immunohistochemistry (IHC) in differentiating OSJ from other jawbone mimickers, such as benign fibro-oss...

  • Article
  • Open Access
29 Citations
6,706 Views
15 Pages

31 May 2018

The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML). Moreover, fms like tyrosine...

(This article belongs to the Special Issue p53 Signaling in Cancers)
  • Article
  • Open Access
1 Citations
1,684 Views
23 Pages

PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells

  • Yeongji Kim,
  • Jin-Woo Kim,
  • Junwon Choi,
  • Jinhyeong Kim and ,
  • Soyeon Park,
  • Wonji Choi,
  • Hyunju An,
  • Jinman Kim,
  • Minsup Kim and
  • Soonchul Lee
  • + 8 authors+ 3 authors

5 March 2026

Osteosarcoma, the most common malignant bone tumor in young individuals, often exhibits poor outcomes due to MDM2-mediated suppression of the p53 pathway. Whereas conventional MDM2 inhibitors block the p53–MDM2 interaction but frequently induce...

of 18